{"type":"rich","version":"1.0","title":"What can we learn from 2024’s biotech IPOs?    ","author_name":"The Top Line","author_url":"https://www.fiercebiotech.com/podcasts","provider_name":"Omny Studio","provider_url":"https://omny.fm","html":"<iframe src=\"https://omny.fm/shows/the-top-line/what-can-we-learn-from-2024-s-biotech-ipos/embed\" width=\"100%\" height=\"180\" allow=\"autoplay; clipboard-write; fullscreen\" allowfullscreen frameborder=\"0\" title=\"What can we learn from 2024’s biotech IPOs?    \"></iframe>","width":600,"height":180}